GENE ONLINE|News &
Day 4 ASCO 2021 Roundup: Immunotherapy Candidates Show Promise in Early Studies
The fourth day of the ASCO 2021 virtual annual meeting featured clinical trial data of some promising immunotherapy candidates.
Oncolytic Viral Therapy Shows Promising Results in Fighting T-cell Lymphoma. Joselle Cook, MBBS, from the Mayo Clinic presented the results of Phase 1 clinical trial testing the effects of a novel oncolytic virotherapy against hematological malignancies.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
